RIPK1 inhibition reduced inflammation and keratinocyte cell death in lichen planus and CLE models. Could this be a new ...

A potential breakthrough in the treatment of type 1 mediated chronic inflammatory skin diseases (ISD) has emerged, as ...

Longeveron® Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with ...

Subcutaneous (SC) amivantamab reduces administration from hours to minutes, with efficacy and safety consistent with intravenous (IV) amivantamab1,2,3,4,5 SC amivantamab is now authorised across all ...

The OriGAMI-4 trial reveals subcutaneous Rybrevant's 45% response rate in metastatic head and neck cancer patients after ...

Human epidermal growth factor receptor 2 (HER2)–positive (HER2+) breast cancers make up  15% to 20% of all breast tumors. In ...

Printing” skin grafts can improve patient quality of life after injury, but the technology faces barriers before it can become commercially available.

That said, Medik8’s liquid peptides advanced MP serum (was £79, now £63, Medik8.com) makes some bold anti-ageing skincare ...

The trend of consuming matcha, which is claimed to promote beautiful and glowing skin, is gaining popularity. A food expert responds to this claim.

The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for subcutaneous Rybrevant Faspro ...

“Many confounding factors in real life—including lifestyle, UV exposure, occupational hazards, and immune status—can ...

As of Wednesday, February 25, CytomX Therapeutics, Inc.’s CTMX share price has surged by 7.44%, which has investors questioning if this is right time to sell.